Skip Navigation


JAC Advance Access originally published online on November 25, 2004
Journal of Antimicrobial Chemotherapy 2004 54(6):1051-1056; doi:10.1093/jac/dkh504
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
54/6/1051    most recent
dkh504v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Messer, S. A.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Messer, S. A.
Right arrow Articles by Jones, R. N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

JAC vol.54 no.6 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved

Initial results from a longitudinal international surveillance programme for anidulafungin (2003)

Shawn A. Messer1,*, Jeffrey T. Kirby1, Helio S. Sader1, Thomas R. Fritsche1 and Ronald N. Jones1,2

1 The JONES Group/JMI Laboratories, Inc., 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317; 2 Tufts University School of Medicine, Boston, MA, USA

* Corresponding author. Tel: +1-319-665-3370; Fax: +1-319-665-3371; Email: shawn-messer{at}jmilabs.com

Objectives: This longitudinal study evaluated the in vitro activity of anidulafungin against 880 clinical yeast isolates and 68 mould isolates from 64 medical centres in North America, Latin America and Europe.

Methods: MICs of anidulafungin, amphotericin B, 5-fluorocytosine, fluconazole, itraconazole, ketoconazole and voriconazole were determined using reference method (M27-A2) guidelines. The M38-A reference method was used for the filamentous fungi, including determination of minimum effective concentrations (MECs) of anidulafungin.

Results: Anidulafungin was more active when compared with fluconazole and itraconazole for Candida albicans (MIC90, 0.06 mg/L), Candida tropicalis (MIC90, 0.06 mg/L), Candida glabrata (MIC90, 0.12 mg/L), Candida krusei (MIC90, 0.06 mg/L) and Candida lusitaniae (MIC90, 1 mg/L) as well as the less-often encountered yeast species. Anidulafungin was less active against Candida parapsilosis, Candida guilliermondii and Candida famata (MIC50, 1–2 mg/L). Anidulafungin also exhibited excellent activity against all Aspergillus spp. (MEC90, ≤0.03 mg/L). Anidulafungin was also evaluated comparing two end point reading criteria and two incubation intervals. Data indicate that longer incubation periods do not significantly influence overall MIC ranges. These international surveillance results for anidulafungin confirm the activity observed in studies of smaller numbers of isolates.

Keywords: yeast , susceptibility , antifungals , echinocandins


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
N. P. Wiederhold, L. K. Najvar, R. Bocanegra, D. Molina, M. Olivo, and J. R. Graybill
In Vivo Efficacy of Anidulafungin and Caspofungin against Candida glabrata and Association with In Vitro Potency in the Presence of Sera
Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1616 - 1620.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Cota, M. Carden, J. R. Graybill, L. K. Najvar, D. S. Burgess, and N. P. Wiederhold
In Vitro Pharmacodynamics of Anidulafungin and Caspofungin against Candida glabrata Isolates, Including Strains with Decreased Caspofungin Susceptibility
Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3926 - 3928.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. Gumbo, G. L. Drusano, W. Liu, L. Ma, M. R. Deziel, M. F. Drusano, and A. Louie
Anidulafungin Pharmacokinetics and Microbial Response in Neutropenic Mice with Disseminated Candidiasis
Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3695 - 3700.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. A. Pfaller, D. J. Diekema, L. Boyken, S. A. Messer, S. Tendolkar, R. J. Hollis, and B. P. Goldstein
Effectiveness of Anidulafungin in Eradicating Candida Species in Invasive Candidiasis
Antimicrob. Agents Chemother., November 1, 2005; 49(11): 4795 - 4797.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
M. A. Pfaller, L. Boyken, S. A. Messer, S. Tendolkar, R. J. Hollis, and D. J. Diekema
Comparison of Results of Voriconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program
J. Clin. Microbiol., October 1, 2005; 43(10): 5208 - 5213.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.